[go: up one dir, main page]

NO20066074L - Irinotecanpreparat - Google Patents

Irinotecanpreparat

Info

Publication number
NO20066074L
NO20066074L NO20066074A NO20066074A NO20066074L NO 20066074 L NO20066074 L NO 20066074L NO 20066074 A NO20066074 A NO 20066074A NO 20066074 A NO20066074 A NO 20066074A NO 20066074 L NO20066074 L NO 20066074L
Authority
NO
Norway
Prior art keywords
irinotecan
mol
closed
salt
water phase
Prior art date
Application number
NO20066074A
Other languages
English (en)
Inventor
Seigo Sawada
Takeshi Matsuzaki
Keisuke Yoshino
Shigenori Nozawa
Masashi Isozaki
Ikuo Kato
Original Assignee
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk
Publication of NO20066074L publication Critical patent/NO20066074L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Irinotekanpreparat som har irinotekan og/eller et salt derav sterkt båret av en lukket vesikkelbærer, som oppviser en bemerkelsesverdig forlenget retensjon i blod sammenlignet med den til vanlige irinotekanliposompreparater, og som er i stand til å være til stede i blod i et langvarig tidsrom. Det er tilveiebrakt et irinotekanpreparat som omfatter lukkede vesikler dannet av en lipidmembran hvori irinotekan og/eller et salt derav er innelukket ved en konsentrasjon på minst 0,07 mol/mol (legemiddel-mol/totalmembranlipid-mol). Irinotekanpreparatet har fortrinnsvis en ionegradient mellom en indre vannfase og en ytre vannfase i de lukkede vesikler. De lukkede vesikler er fortrinnsvis liposomer, og liposomene har fortrinnsvis bare den utvendige overflate derav modifisert med et overflatemodifiseringsmiddel som inneholder en hydrofil polymer.
NO20066074A 2004-06-01 2006-12-29 Irinotecanpreparat NO20066074L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004163742 2004-06-01
PCT/JP2005/009953 WO2005117878A1 (ja) 2004-06-01 2005-05-31 イリノテカン製剤

Publications (1)

Publication Number Publication Date
NO20066074L true NO20066074L (no) 2007-02-28

Family

ID=35462721

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066074A NO20066074L (no) 2004-06-01 2006-12-29 Irinotecanpreparat

Country Status (24)

Country Link
US (1) US7846473B2 (no)
EP (1) EP1752150B1 (no)
JP (1) JP4885715B2 (no)
KR (1) KR100889139B1 (no)
CN (1) CN1960729B (no)
AP (1) AP2255A (no)
AR (1) AR049137A1 (no)
AU (1) AU2005249314B2 (no)
BR (1) BRPI0511753A (no)
CA (1) CA2567857C (no)
CR (1) CR8768A (no)
EA (1) EA011612B1 (no)
EC (1) ECSP067041A (no)
ES (1) ES2594621T3 (no)
GE (1) GEP20094620B (no)
IL (1) IL179558A0 (no)
MX (1) MXPA06013874A (no)
NO (1) NO20066074L (no)
NZ (1) NZ551748A (no)
TN (1) TNSN06395A1 (no)
TW (1) TWI362931B (no)
UA (1) UA85099C2 (no)
WO (1) WO2005117878A1 (no)
ZA (1) ZA200610204B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2424792C2 (ru) 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств
US20090196917A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
CA2724408A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
WO2010058840A1 (ja) * 2008-11-20 2010-05-27 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
ES2547698T3 (es) * 2009-12-03 2015-10-08 Jiangsu Hengrui Medicine Co., Ltd. Liposoma de irinotecán o su clorhidrato y método de preparación del mismo
CN103120645B (zh) * 2009-12-03 2015-03-11 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
US10391056B2 (en) 2011-11-03 2019-08-27 Taiwan Lipsome Company, LTD. Pharmaceutical compositions of hydrophobic camptothecin derivatives
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
EP2892509B1 (en) * 2012-09-04 2024-12-11 Lauren Sciences LLC Bolaamphiphilic compounds, compositions and uses thereof
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
CN105982857B (zh) * 2015-02-09 2019-03-08 湖南科伦药物研究有限公司 一种盐酸伊立替康脂质体组合物及其制备方法
ES2589320B2 (es) * 2015-04-14 2017-06-01 Universidad Politécnica de Madrid Sistema de compartimentación de espacios con membranas enrollables
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR101646181B1 (ko) * 2015-08-18 2016-08-05 한양대학교 에리카산학협력단 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물
HK1257216A1 (zh) 2015-08-20 2019-10-18 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法
BR112018002941B1 (pt) 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
BR112018006922B1 (pt) 2015-10-16 2023-11-21 Ipsen Biopharm Ltd Composições de irinotecano lipossômico estabilizado para armazenamento
CN110402163A (zh) * 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
CN109260155B (zh) 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
CN117547535A (zh) 2021-10-15 2024-02-13 昆山新蕴达生物科技有限公司 包含抗肿瘤药物的组合物及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
CA2346879A1 (en) 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
DE60042159D1 (en) 1999-06-25 2009-06-18 Terumo Corp Liposome
JP2001064158A (ja) * 1999-06-25 2001-03-13 Terumo Corp リポソーム
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AU7038501A (en) * 2000-06-30 2002-01-14 Inex Pharmaceuticals Corp Liposomal antineoplastic drugs and uses thereof
ATE345775T1 (de) * 2001-10-03 2006-12-15 Celator Pharmaceuticals Inc Zusammensetzungen zur verabreichung von arzneimittelkombinationen
AU2002331481B2 (en) 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
EP1448165B1 (en) * 2001-11-13 2007-09-19 Celator Pharmaceuticals, Inc. Lipid carrier compositions and methods for improved drug retention
EP1443900B1 (en) * 2001-11-13 2012-05-23 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
US20060193902A1 (en) * 2003-04-02 2006-08-31 Celator Pharmaceuticals, Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
RU2424792C2 (ru) 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain

Also Published As

Publication number Publication date
AP2006003837A0 (en) 2006-12-31
CR8768A (es) 2007-08-28
CN1960729A (zh) 2007-05-09
EP1752150B1 (en) 2016-08-31
NZ551748A (en) 2010-02-26
BRPI0511753A (pt) 2008-01-02
JP4885715B2 (ja) 2012-02-29
TNSN06395A1 (en) 2008-02-22
AR049137A1 (es) 2006-06-28
IL179558A0 (en) 2007-07-04
WO2005117878A1 (ja) 2005-12-15
EA011612B1 (ru) 2009-04-28
ES2594621T3 (es) 2016-12-21
AU2005249314A1 (en) 2005-12-15
GEP20094620B (en) 2009-02-25
KR20070037440A (ko) 2007-04-04
US20080069868A1 (en) 2008-03-20
EP1752150A4 (en) 2012-06-20
AP2255A (en) 2011-07-21
US7846473B2 (en) 2010-12-07
CA2567857A1 (en) 2005-12-15
MXPA06013874A (es) 2007-04-25
AU2005249314B2 (en) 2008-09-11
TWI362931B (en) 2012-05-01
EP1752150A1 (en) 2007-02-14
ZA200610204B (en) 2008-01-30
ECSP067041A (es) 2006-12-29
EA200602246A1 (ru) 2007-04-27
UA85099C2 (en) 2008-12-25
CA2567857C (en) 2009-12-22
CN1960729B (zh) 2012-04-11
KR100889139B1 (ko) 2009-03-17
TW200600095A (en) 2006-01-01
JPWO2005117878A1 (ja) 2008-04-03

Similar Documents

Publication Publication Date Title
NO20066074L (no) Irinotecanpreparat
Kim et al. Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression
Kahya et al. Raft partitioning and dynamic behavior of human placental alkaline phosphatase in giant unilamellar vesicles
Stoimenovski et al. Enhanced membrane transport of pharmaceutically active protic ionic liquids
Machado et al. Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective
Pata et al. Membrane solubilization by detergent: resistance conferred by thickness
BRPI0506831A (pt) proteìnas de andaime de membrana
Todo et al. Permeation pathway of macromolecules and nanospheres through skin
BR0113477A (pt) Peptìdios de penetração em membranas e usos dos mesmos
ES2303114T3 (es) Metodo para cargar medicamentos en liposomas.
Malovrh et al. Characterization of hemolytic activity of 3-alkylpyridinium polymers from the marine sponge Reniera sarai
ITMI20020189A1 (it) Composizione per uso farmaceutico o dietetico per contrastare la caduta dei capelli
Dathe et al. Proline at position 14 of alamethicin is essential for hemolytic activity, catecholamine secretion from chromaffin cells and enhanced metabolic activity in endothelial cells
Sadzuka et al. Effective irinotecan (CPT‐11)‐containing liposomes: intraliposomal conversion to the active metabolite SN‐38
Tavano et al. New sucrose cocoate based vesicles: preparation characterization and skin permeation studies
Matsuo et al. Possible effects of hepatocyte growth factor for the prevention of peritoneal fibrosis
Vitiello et al. The iAβ5p β-breaker peptide regulates the Aβ (25–35) interaction with lipid bilayers through a cholesterol-mediated mechanism
Flanigan How should dialysis fluid be individualized for the chronic hemodialysis patient?
Hoshi et al. Hydrogen ion-coupled transport of D-glucose by phlorizin-sensitive sugar carrier in intestinal brush-border membranes
Sato et al. Induction of the expression of cardioprotective proteins after mild-to-moderate consumption of alcohol
Heller et al. Changes in lipid bilayer structure caused by the helix-to-sheet transition of an HIV-1 gp41 fusion peptide derivative
CN101199273B (zh) 一种新型多器官储存保护液
US9211313B2 (en) Methods and compound to inhibit Ca2+ permeable cation conductance
Tokuoka et al. Circular dichroism studies on the interaction between human serum albumin and thyroxine
KR20210040509A (ko) 경피투과펩티드에 의한 hapln1의 피부흡수증진 조성물

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application